Puma Gross Profit from 2010 to 2026

PBYI Stock

USD 6.75 0.07 1.03%

Puma Biotechnology's Gross Profit is increasing with slightly volatile movements from year to year. Gross Profit is predicted to flatten to about 106.8 M. Gross Profit is the profit Puma Biotechnology makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2011-03-31

Previous Quarter

40.1 M

Current Value

42.3 M

Quarterly Volatility

24.9 M

Credit Downgrade

Yuan Drop

Covid

Interest Hikes

Check Puma Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Puma Biotechnology's main balance sheet or income statement drivers, such as Interest Expense of 15 M, Other Operating Expenses of 179.8 M or Operating Income of 37.4 M, as well as many indicators such as Price To Sales Ratio of 0.61, Dividend Yield of 0.0 or PTB Ratio of 1.76. Puma financial statements analysis is a perfect complement when working with Puma Biotechnology Valuation or Volatility modules.

Build AI portfolio with Puma Stock

Check out the analysis of Puma Biotechnology Correlation against competitors.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

The Gross Profit trend for Puma Biotechnology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Puma Biotechnology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Puma Biotechnology's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Puma Biotechnology over the last few years. Gross profit is a required income statement account that reflects total revenue of Puma Biotechnology minus its cost of goods sold. It is profit before Puma Biotechnology operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Puma Biotechnology's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Puma Biotechnology's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 163.04 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Puma Gross Profit Regression Statistics

	Arithmetic Mean	97,432,236
	Geometric Mean	0.00
	Coefficient Of Variation	98.39
	Mean Deviation	89,393,539
	Median	106,769,607
	Standard Deviation	95,861,778
	Sample Variance	9189.5T
	Range	236.6M
	R-Value	0.76
	Mean Square Error	4102.8T
	R-Squared	0.58
	Significance	0.0004
	Slope	14,475,256
	Total Sum of Squares	147031.7T

Puma Gross Profit History

	2026	106.8 M
	2025	191 M
	2024	166.1 M
	2023	173 M
	2022	172.9 M
	2021	189.5 M
	2020	185.7 M

Other Fundumenentals of Puma Biotechnology

Gross Profit Margin

Puma Biotechnology Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Total Liab	Total Current Assets	Common Stock	Retained Earnings	Accounts Payable	Net Tangible Assets	Short Term Investments	Capital Surpluse	Deferred Long Term Liab	Property Plant Equipment	Net Receivables	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Capital Stock	Current Deferred Revenue
Total Assets		0.2	0.2	0.69	0.89	-0.64	-0.78	0.5	-0.13	0.3	0.83	0.31	0.31	0.5	0.57	0.38	-0.47	0.24	-0.42	0.29	-0.25
Total Stockholder Equity	0.2		-0.75	-0.58	0.56	-0.28	0.33	0.18	0.9	0.57	-0.2	0.26	-0.18	-0.42	-0.42	-0.03	0.58	-0.12	0.58	0.0	0.03
Net Debt	0.2	-0.75		0.72	-0.16	0.06	-0.58	0.01	-0.8	-0.02	0.5	-0.34	0.14	0.63	0.67	0.34	-0.62	0.24	-0.57	0.28	-0.29
Total Liab	0.69	-0.58	0.72		0.33	-0.32	-0.9	0.29	-0.78	-0.18	0.85	0.06	0.39	0.73	0.79	0.35	-0.83	0.29	-0.77	0.25	-0.24
Total Current Assets	0.89	0.56	-0.16	0.33		-0.63	-0.44	0.53	0.28	0.53	0.53	0.42	0.2	0.16	0.32	0.29	-0.24	0.29	-0.19	0.1	-0.07
Common Stock	-0.64	-0.28	0.06	-0.32	-0.63		0.39	-0.36	0.02	-0.2	-0.41	-0.17	-0.16	-0.2	-0.23	-0.15	0.17	-0.07	0.14	-0.15	0.15
Retained Earnings	-0.78	0.33	-0.58	-0.9	-0.44	0.39		-0.36	0.61	0.13	-0.97	-0.14	-0.32	-0.79	-0.75	-0.46	0.59	-0.18	0.51	-0.47	0.49
Accounts Payable	0.5	0.18	0.01	0.29	0.53	-0.36	-0.36		0.03	0.41	0.36	0.73	0.33	-0.21	0.09	-0.04	-0.29	0.32	-0.22	-0.32	0.32
Net Tangible Assets	-0.13	0.9	-0.8	-0.78	0.28	0.02	0.61	0.03		0.51	-0.52	0.18	-0.28	-0.58	-0.62	-0.24	0.64	-0.11	0.55	-0.2	0.18
Short Term Investments	0.3	0.57	-0.02	-0.18	0.53	-0.2	0.13	0.41	0.51		-0.07	0.05	-0.01	-0.31	-0.1	-0.02	0.07	0.15	0.09	-0.18	0.19
Capital Surpluse	0.83	-0.2	0.5	0.85	0.53	-0.41	-0.97	0.36	-0.52	-0.07		0.17	0.3	0.77	0.72	0.52	-0.49	0.16	-0.44	0.54	-0.5
Deferred Long Term Liab	0.31	0.26	-0.34	0.06	0.42	-0.17	-0.14	0.73	0.18	0.05	0.17		0.21	-0.31	0.07	0.14	-0.09	0.5	-0.09	-0.31	0.32
Property Plant Equipment	0.31	-0.18	0.14	0.39	0.2	-0.16	-0.32	0.33	-0.28	-0.01	0.3	0.21		0.08	0.15	-0.24	-0.19	-0.12	-0.47	-0.31	0.39
Net Receivables	0.5	-0.42	0.63	0.73	0.16	-0.2	-0.79	-0.21	-0.58	-0.31	0.77	-0.31	0.08		0.73	0.55	-0.43	0.08	-0.41	0.72	-0.73
Long Term Debt Total	0.57	-0.42	0.67	0.79	0.32	-0.23	-0.75	0.09	-0.62	-0.1	0.72	0.07	0.15	0.73		0.79	-0.64	0.59	-0.51	0.5	-0.48
Net Invested Capital	0.38	-0.03	0.34	0.35	0.29	-0.15	-0.46	-0.04	-0.24	-0.02	0.52	0.14	-0.24	0.55	0.79		-0.17	0.58	0.01	0.7	-0.65
Short Long Term Debt	-0.47	0.58	-0.62	-0.83	-0.24	0.17	0.59	-0.29	0.64	0.07	-0.49	-0.09	-0.19	-0.43	-0.64	-0.17		-0.5	0.83	0.15	-0.08
Net Working Capital	0.24	-0.12	0.24	0.29	0.29	-0.07	-0.18	0.32	-0.11	0.15	0.16	0.5	-0.12	0.08	0.59	0.58	-0.5		-0.42	-0.07	0.04
Short Term Debt	-0.42	0.58	-0.57	-0.77	-0.19	0.14	0.51	-0.22	0.55	0.09	-0.44	-0.09	-0.47	-0.41	-0.51	0.01	0.83	-0.42		0.22	-0.21
Capital Stock	0.29	0.0	0.28	0.25	0.1	-0.15	-0.47	-0.32	-0.2	-0.18	0.54	-0.31	-0.31	0.72	0.5	0.7	0.15	-0.07	0.22		-0.95
Current Deferred Revenue	-0.25	0.03	-0.29	-0.24	-0.07	0.15	0.49	0.32	0.18	0.19	-0.5	0.32	0.39	-0.73	-0.48	-0.65	-0.08	0.04	-0.21	-0.95

Click cells to compare fundamentals

About Puma Biotechnology Financial Statements

Investors use fundamental indicators, such as Puma Biotechnology's Gross Profit, to determine how well the company is positioned to perform in the future. Although Puma Biotechnology's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.

	Last Reported	Projected for Next Year
Gross Profit	191 M	106.8 M
Gross Profit Margin	0.83	0.87

Currently Active Assets on Macroaxis

FSLY	Fastly Class A
MOB	Mobilicom Limited American
CMG	Chipotle Mexican Grill
CSAN	Cosan SA ADR
RKT	Rocket Companies

When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:

How To Invest In Puma

Details

Is Puma Stock a good investment?

Details

What is Puma Biotechnology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Puma Biotechnology Correlation against competitors.

For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.

You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.

Is there potential for Biotechnology market expansion? Will Puma introduce new products? Factors like these will boost the valuation of Puma Biotechnology. Anticipated expansion of Puma directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.58)

Earnings Share

0.74

Revenue Per Share

4.267

Quarterly Revenue Growth

(0.32)

Return On Assets

0.099

The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

It's important to distinguish between Puma Biotechnology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Puma Biotechnology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Puma Biotechnology's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

Puma Gross Profit from 2010 to 2026

Latest Puma Biotechnology's Gross Profit Growth Pattern

Puma Gross Profit Regression Statistics

Puma Gross Profit History

Other Fundumenentals of Puma Biotechnology

Puma Biotechnology Gross Profit component correlations

About Puma Biotechnology Financial Statements

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY